Neoleukin Therapeutics (NASDAQ:NLTX) Shares Down 1.2%

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) traded down 1.2% during mid-day trading on Thursday . The company traded as low as $28.09 and last traded at $29.87. 71,109 shares traded hands during trading, an increase of 42% from the average session volume of 50,104 shares. The stock had previously closed at $30.23.

Neoleukin Therapeutics Price Performance

The business’s fifty day moving average is $37.24 and its 200-day moving average is $25.52. The firm has a market cap of $280.72 million, a PE ratio of -9.60 and a beta of 1.11.

Institutional Trading of Neoleukin Therapeutics

A hedge fund recently raised its stake in Neoleukin Therapeutics stock. BML Capital Management LLC raised its holdings in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) by 315.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,664 shares of the company’s stock after purchasing an additional 74,915 shares during the period. Neoleukin Therapeutics accounts for about 0.4% of BML Capital Management LLC’s holdings, making the stock its 22nd biggest position. BML Capital Management LLC owned 1.12% of Neoleukin Therapeutics worth $390,000 at the end of the most recent quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.